KRAS and non-small cell lung carcinoma: In the transgenic KRastm4Tuj/Trp53tm1Brn mouse model [11, 12], inhalation of adenovirus bearing the Cre recombinase [13] induces activating mutation of KRas in parallel with inactivation of Trp53. In this system, introduction of adenovirally-borne Cre at post-natal week 10 results in development of lung adenomas at ~ 5–5.5 months of age (~22 weeks), progressing to adenocarcinomas and leading to severe lung tumor burden at 6–7 months of age [11], with tumors that conserve many pathological and molecular features of human NSCLC [14].